Publications by authors named "Gunter Muth"

Claim this Profile
G
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.
Sylvia Herter, Frank Herting, Gunter Muth, Erwin van Puijenbroek, Tilman Schlothauer

Haematologica· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.
Frank Herting, Thomas Friess, Sabine Bader, Gunter Muth, Gabriele Hölzlwimmer

Leuk Lymphoma· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Gunter Muth

Mol Cancer Ther· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis